{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=36&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Miami",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 12523,
    "total_pages": 1253,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=37&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Miami&page=35&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T00:00:43.224Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01767857",
      "title": "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Xilonix",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2013-03-31",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-29",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767857"
    },
    {
      "nct_id": "NCT00648154",
      "title": "Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Letrozole Tablets 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Femara® Tablets 2.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2005-11",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2009-12-01",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648154"
    },
    {
      "nct_id": "NCT06179875",
      "title": "An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Veligrotug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2024-01-31",
      "completion_date": "2025-06-23",
      "has_results": true,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06179875"
    },
    {
      "nct_id": "NCT03486912",
      "title": "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Cirrhosis",
        "Liver Fibrosis",
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 155,
      "start_date": "2018-06-12",
      "completion_date": "2021-09-14",
      "has_results": true,
      "last_update_posted_date": "2022-10-13",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 85,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486912"
    },
    {
      "nct_id": "NCT03974100",
      "title": "Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postmenopausal Women With Osteoporosis"
      ],
      "interventions": [
        {
          "name": "GP2411",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EU-Prolia (EU-authorized Prolia®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "55 Years to 80 Years · Female only"
      },
      "enrollment_count": 527,
      "start_date": "2019-07-02",
      "completion_date": "2022-04-22",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 6,
      "location_summary": "Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Wyomissing",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03974100"
    },
    {
      "nct_id": "NCT00862641",
      "title": "A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Coronary Artery Disease",
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1009,
      "start_date": "2009-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-09-18",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 48,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862641"
    },
    {
      "nct_id": "NCT00232154",
      "title": "A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sinusitis"
      ],
      "interventions": [
        {
          "name": "Zithromax™ (azithromycin) 500mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Endoscopic Sinus Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling for hematology",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood sampling for plasma chemistry profile",
          "type": "PROCEDURE"
        },
        {
          "name": "Serum pregnancy test (for women of child-bearing potential)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2005-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2011-04-21",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 18,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 11 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00232154"
    },
    {
      "nct_id": "NCT03698994",
      "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Ependymal Tumor",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Histiocytic and Dendritic Cell Neoplasm",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-11-14",
      "completion_date": "2027-03-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 105,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698994"
    },
    {
      "nct_id": "NCT02900222",
      "title": "Study of Choroid Plexus Cauterization in Patients With Hydrocephalus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hydrocephalus"
      ],
      "interventions": [
        {
          "name": "endoscopic choroid plexus coagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Ronald Benveniste",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2016-09-01",
      "completion_date": "2018-05-16",
      "has_results": false,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900222"
    },
    {
      "nct_id": "NCT04524351",
      "title": "Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Posiphen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annovis Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2020-08-14",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-02-28",
      "last_synced_at": "2026-11-06T00:00:43.224Z",
      "location_count": 13,
      "location_summary": "Stamford, Connecticut • DeLand, Florida • Hallandale, Florida + 9 more",
      "locations": [
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04524351"
    }
  ]
}